Literature DB >> 20428647

Prevalence of phenotypic resistance of Staphylococcus aureus isolates to macrolide, lincosamide, streptogramin B, ketolid and linezolid antibiotics in Turkey.

Riza Adaleti1, Yasar Nakipoglu, Nurgul Ceran, Cihan Tasdemir, Fatma Kaya, Semiha Tasdemir.   

Abstract

The incidence of drug-resistant pathogens differs greatly between countries according to differences in the usage of antibiotics. The purpose of this study was to investigate the phenotypic resistance of 321 methicillin resistance Staphylococcus aureus (MRSA) and 195 methicillin susceptible S. aureus (MSSA) in a total of 516 S. aureus strains to macrolide, lincosamide, streptogramin B (MLS B), ketolid, and linezolid. Disk diffusion method was applied to determine MLS B phenotype and susceptibility to different antibiotic agents. It was found that 54.6% of the isolates were resistant to erythromycin (ERSA), 48% to clindamycin, 55% to azithromycin, 58.7% to spiramycin, 34.7% to telithromycin, and 0.4% to quinupristin-dalfopristin, respectively. No strain resistant to linezolid was found. The prevalence of constitutive (cMLS B), inducible (IMLS B), and macrolides and type B streptogramins (M/MS B) among ERSA isolates (237 MRSA, 45 MSSA) was 69.6 %, 18.2%, and 12.2 % in MRSA and 28.9%, 40%, and 31.1% in MSSA, respectively. In conclusions, the prevalence of cMLS B was predominant in MRSA; while in MSSA strains, iMLS B and M/MS B phenotype were more higher than cMLS B phenotype resistance. The resistance to quinupristindalfopristin was very low, and linezolid was considered as the most effective antibiotic against all S.aureus strains.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20428647     DOI: 10.1590/s1413-86702010000100003

Source DB:  PubMed          Journal:  Braz J Infect Dis        ISSN: 1413-8670            Impact factor:   1.949


  7 in total

1.  Crystal structure of the synergistic antibiotic pair, lankamycin and lankacidin, in complex with the large ribosomal subunit.

Authors:  Matthew J Belousoff; Tal Shapira; Anat Bashan; Ella Zimmerman; Haim Rozenberg; Kenji Arakawa; Haruyasu Kinashi; Ada Yonath
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

2.  Epidemiology of Staphylococcus aureus in Bangalore, India: emergence of the ST217 clone and high rate of resistance to erythromycin and ciprofloxacin in the community.

Authors:  C Bouchiat; N El-Zeenni; B Chakrakodi; S Nagaraj; G Arakere; J Etienne
Journal:  New Microbes New Infect       Date:  2015-05-14

3.  Evaluation of Antimicrobial Resistance in Staphylococcus aureus Isolates by Years.

Authors:  Cennet Rağbetli; Mehmet Parlak; Yasemin Bayram; Huseyin Guducuoglu; Nesrin Ceylan
Journal:  Interdiscip Perspect Infect Dis       Date:  2016-05-09

4.  The effect of fennel essential oil and trans-anethole on antibacterial activity of mupirocin against Staphylococcus aureus isolated from asymptomatic carriers.

Authors:  Paweł Kwiatkowski; Agata Pruss; Helena Masiuk; Magdalena Mnichowska-Polanowska; Maciej Kaczmarek; Stefania Giedrys-Kalemba; Barbara Dołęgowska; Hanna Zielińska-Bliźniewska; Jurek Olszewski; Monika Sienkiewicz
Journal:  Postepy Dermatol Alergol       Date:  2019-06-18       Impact factor: 1.837

5.  Azithromycin, fluoroquinolone and chloramphenicol resistance of non-chlamydia conjunctival bacteria in rural community of Ethiopia.

Authors:  Bayeh Abera; Mulugeta Kibret
Journal:  Indian J Ophthalmol       Date:  2014-02       Impact factor: 1.848

Review 6.  Antibiotic Resistance Patterns and Virulence Determinants of Different SCCmec and Pulsotypes of Staphylococcus Aureus Isolated from a Major Hospital in Ilam, Iran.

Authors:  Mehdi Abbasi; Majid BaseriSalehi; Nima Bahador; Morovat Taherikalani
Journal:  Open Microbiol J       Date:  2017-10-31

7.  Phenotypic and genotypic characterization of macrolide, lincosamide and streptogramin B resistance among clinical isolates of staphylococci in southwest of Iran.

Authors:  Reza Khashei; Yalda Malekzadegan; Hadi Sedigh Ebrahim-Saraie; Zahra Razavi
Journal:  BMC Res Notes       Date:  2018-10-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.